ALZAMEND NEURO INC (ALZN) Stock News
NASDAQ:ALZN - Nasdaq - US02262M5067 - Common Stock - Currency: USD
ALZN Latest News, Press Relases and Analysis
Why Nintendo Stock Is Jumping Today
Nintendo (OTC: NTDOY) stock is posting gains in Tuesday's trading. The stock market rallied early in today's trading following news that the Trump administration had started preliminary tariff negotiations with Japan and other countries. While the relief rally for the broader market faded, the news of trade negotiations with Japan is powering gains for Nintendo stock.
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Alzamend Neuro, Inc. (NASDAQ:ALZN) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]
Mentions: COMP
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits
Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and reduced systemic side effects.
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects
Alzamend Neuro to Present at the Sequire Investor Summit
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
Alzamend Neuro Inc. (NASDAQ:ALZN) has partnered with Massachusetts General Hospital as its contract research organization to conduct a Phase 2 clinical trial of AL001 for Alzheimer’s. A healthy subjects cohort will also be studied to permit comparisons of their plasma and brain pharmacokinetics to that of Alzheimer’s patients. Also Read: EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares. The objective of this trial is to assess the comparative increase in li
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Alzamend Neuro Issues Letter to Stockholders
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
